For example, programmed death ligand 1 (PD-L1)2 expression in tumor tissue is predictive of a higher response rate to programmed death 1 (PD-1) or PD-L1 inhibitor therapy in patients with non-small cell lung cancer (NSCLC)3–5. This evidence concerns the gene CD274 and non-small cell lung carcinoma.